Business Wire

Blinkist Chooses Monte Carlo to Deliver More Reliable Data Pipelines Through Data Observability

Share

Monte Carlo, the data reliability company, today announced Berlin-based microlearning app Blinkist has selected Monte Carlo to achieve more reliable data through data observability.

As a high-growth company with over 16 million users worldwide, Blinkist leverages paid performance marketing to fuel customer acquisition — and those channels rely on accurate behavioral data to optimize campaign spend. Like many companies today, Blinkist’s data engineering teams have been challenged by broken pipelines, missing or inaccurate data, and a subsequent lack of trust in data across their organization.

Monte Carlo is an end-to-end Data Observability Platform that enables data teams at companies like Blinkist to seamlessly monitor the health of their data assets by applying the proven principles of application observability to data. Simultaneously, Monte Carlo provides CDOs and other data stakeholders with a holistic view of their company’s data health and reliability across critical business use cases.

“For Blinkist, having trustworthy and reliable data is foundational to the success of our business. When the pandemic hit, real-time data became even more crucial to understand the reality of our audience’s daily lives,” stated Gopi Krishnamurthy, Director of Engineering at Blinkist. “Any inaccuracies were both timely and costly; our team was spending 50% of their time on fixing these. Monte Carlo enabled us to adopt data reliability engineering principles and increased transparency about data health across the company.”

After onboarding Monte Carlo, the platform’s automated monitoring and intelligent alerting has already allowed Blinkist data engineers to reclaim up to 120 hours per week and enabled them to focus on innovation and product, rather than firefighting data issues. The Monte Carlo platform also helps their team build organizational trust in data by providing visibility into issues, and delivers the confidence Blinkist engineers need to implement and maintain data-specific Service Level Agreements (SLAs).

With more reliable and accurate data in place, Blinkist marketers can now make swift decisions to improve targeting and performance, leading to higher overall revenue for the company.

“We are thrilled that Blinkist has chosen Monte Carlo as their data reliability partner,” stated Barr Moses, CEO and co-founder of Monte Carlo. “In today’s environment, data is a company’s most critical asset. Our team is proud to help Blinkist unlock the potential of their data.”

About Monte Carlo

As businesses increasingly rely on data to drive better decision making, it’s mission-critical that this data is accurate and reliable. Billed by Forbes as the New Relic for data teams and backed by Accel and GGV, Monte Carlo solves the costly problem of broken data through their fully automated, SOC-2 certified data observability platform.

About Blinkist

Blinkist is a Berlin-based microlearning app that has grown to over 16 million users worldwide since its launch in 2012. A pioneer in new audio learning formats, their library of over 4,000 titles-turned-Blinks includes topics like society and culture, wellness, parenting, leadership, and more. Blinkist products are curated by editorial experts in collaboration with high-profile, expert creators across a wide variety of fields. Their formats include Blinks, Audiobooks, and now, Shortcasts, accessible across all iOS and Android mobile devices.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Molly Vorwerck
Monte Carlo
mvorwerck@montecarlodata.com
949-230-4860

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye